Among women with clinically node-positive breast cancer receiving neoadjuvant chemotherapy, who had 2 or more sentinel lymph nodes (SLNs) examined, the false-negative rate did not meet the predefined criteria in the ACOSOG Z1071 study. The authors speculate that when 2 or more SLNs are identified by a combination of radiotracer and dye mapping in patients who become clinically node-negative after chemotherapy, there may still be a role for staging with SLN biopsy. Read more here.
Study mentioned: Boughey JC, et al. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013 Oct 9;310(14):1455-1461. PMID: 24101169
No comments:
Post a Comment